Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01900704 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4
A Phase 3 study, sponsored by Serenity Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 810
- Enrollment target
NCT01900704: Completed Phase 3 study, sponsored by Serenity Pharmaceuticals.
NCT01900704 is a Phase 3 study that has completed, run by Serenity Pharmaceuticals. The registered enrollment target is 810 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01900704, a Phase 3 study, has completed, sponsored by Serenity Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 810 participants
- Enrollment target
Study Summary
To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia
Primary Outcome
Change was calculated based on the number of mean nocturic episodes per night between baseline through week 12
Interventions
- DRUG Placebo
- DRUG SER120 750 ng
- DRUG SER120 1500 ng
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 810 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-04 |
| Phase | Phase 3 |
What the finished NCT01900704 record still lists
NCT01900704 is an interventional study that assigns participants to a tested intervention. The registered 810 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01900704 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01900704 about?
NCT01900704 is a clinical study titled "Multicenter Study to Investigate SER120 Nasal Spray Formulations in Patients With Nocturia - DB4". To investigate the efficacy and safety of SER120 nasal spray formulations in patients with nocturia
What is the current status of trial NCT01900704?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 810 participants. The study started on 2013-08. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01900704?
The interventions under investigation include: Placebo (DRUG), SER120 750 ng (DRUG), SER120 1500 ng (DRUG).
Who is sponsoring clinical trial NCT01900704?
This trial is sponsored by Serenity Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01900704's enrollment target sits among peer trials
810 409th of 2000 higher than 1,591 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- NCT06065098 · 806 participants · NA
Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia